121 related articles for article (PubMed ID: 17035625)
1. Development of a screening assay for surrogate markers of CHK1 inhibitor-induced cell cycle release.
Fanton CP; Rowe MW; Moler EJ; Ison-Dugenny M; De Long SK; Rendahl K; Shao Y; Slabiak T; Gesner TG; MacKichan ML
J Biomol Screen; 2006 Oct; 11(7):792-806. PubMed ID: 17035625
[TBL] [Abstract][Full Text] [Related]
2. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics.
Chen Z; Xiao Z; Gu WZ; Xue J; Bui MH; Kovar P; Li G; Wang G; Tao ZF; Tong Y; Lin NH; Sham HL; Wang JY; Sowin TJ; Rosenberg SH; Zhang H
Int J Cancer; 2006 Dec; 119(12):2784-94. PubMed ID: 17019715
[TBL] [Abstract][Full Text] [Related]
3. The topoisomerase I poison camptothecin generates a Chk1-dependent DNA damage checkpoint signal in fission yeast.
Wan S; Capasso H; Walworth NC
Yeast; 1999 Jul; 15(10A):821-8. PubMed ID: 10407262
[TBL] [Abstract][Full Text] [Related]
4. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation.
Xiao Z; Xue J; Sowin TJ; Rosenberg SH; Zhang H
Oncogene; 2005 Feb; 24(8):1403-11. PubMed ID: 15608676
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects.
Zhou Y; Gwadry FG; Reinhold WC; Miller LD; Smith LH; Scherf U; Liu ET; Kohn KW; Pommier Y; Weinstein JN
Cancer Res; 2002 Mar; 62(6):1688-95. PubMed ID: 11912141
[TBL] [Abstract][Full Text] [Related]
6. Ku affects the ataxia and Rad 3-related/CHK1-dependent S phase checkpoint response after camptothecin treatment.
Wang H; Wang X; Zhou XY; Chen DJ; Li GC; Iliakis G; Wang Y
Cancer Res; 2002 May; 62(9):2483-7. PubMed ID: 11980637
[TBL] [Abstract][Full Text] [Related]
7. CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo.
Tse AN; Rendahl KG; Sheikh T; Cheema H; Aardalen K; Embry M; Ma S; Moler EJ; Ni ZJ; Lopes de Menezes DE; Hibner B; Gesner TG; Schwartz GK
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):591-602. PubMed ID: 17255282
[TBL] [Abstract][Full Text] [Related]
8. Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350.
Yin MB; Guo B; Vanhoefer U; Azrak RG; Minderman H; Frank C; Wrzosek C; Slocum HK; Rustum YM
Mol Pharmacol; 2000 Mar; 57(3):453-9. PubMed ID: 10692484
[TBL] [Abstract][Full Text] [Related]
9. Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors.
Tao ZF; Wang L; Stewart KD; Chen Z; Gu W; Bui MH; Merta P; Zhang H; Kovar P; Johnson E; Park C; Judge R; Rosenberg S; Sowin T; Lin NH
J Med Chem; 2007 Apr; 50(7):1514-27. PubMed ID: 17352464
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia.
Iacobucci I; Di Rorà AG; Falzacappa MV; Agostinelli C; Derenzini E; Ferrari A; Papayannidis C; Lonetti A; Righi S; Imbrogno E; Pomella S; Venturi C; Guadagnuolo V; Cattina F; Ottaviani E; Abbenante MC; Vitale A; Elia L; Russo D; Zinzani PL; Pileri S; Pelicci PG; Martinelli G
J Hematol Oncol; 2015 Nov; 8():125. PubMed ID: 26542114
[TBL] [Abstract][Full Text] [Related]
11. Novel indication for cancer therapy: Chk1 inhibition sensitizes tumor cells to antimitotics.
Xiao Z; Xue J; Semizarov D; Sowin TJ; Rosenberg SH; Zhang H
Int J Cancer; 2005 Jul; 115(4):528-38. PubMed ID: 15688426
[TBL] [Abstract][Full Text] [Related]
12. CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy.
McNeely S; Beckmann R; Bence Lin AK
Pharmacol Ther; 2014 Apr; 142(1):1-10. PubMed ID: 24140082
[TBL] [Abstract][Full Text] [Related]
13. Chk1 inhibitors for novel cancer treatment.
Tao ZF; Lin NH
Anticancer Agents Med Chem; 2006 Jul; 6(4):377-88. PubMed ID: 16842237
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells.
Koniaras K; Cuddihy AR; Christopoulos H; Hogg A; O'Connell MJ
Oncogene; 2001 Nov; 20(51):7453-63. PubMed ID: 11709716
[TBL] [Abstract][Full Text] [Related]
15. Treatment with the Chk1 inhibitor Gö6976 enhances cisplatin cytotoxicity in SCLC cells.
Thompson R; Meuth M; Woll P; Zhu Y; Danson S
Int J Oncol; 2012 Jan; 40(1):194-202. PubMed ID: 21894433
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug design.
Massey AJ; Stokes S; Browne H; Foloppe N; Fiumana A; Scrace S; Fallowfield M; Bedford S; Webb P; Baker L; Christie M; Drysdale MJ; Wood M
Oncotarget; 2015 Nov; 6(34):35797-812. PubMed ID: 26437226
[TBL] [Abstract][Full Text] [Related]
17. Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents.
Zenvirt S; Kravchenko-Balasha N; Levitzki A
Oncogene; 2010 Nov; 29(46):6149-59. PubMed ID: 20729914
[TBL] [Abstract][Full Text] [Related]
18. The Chk1/Cdc25A pathway as activators of the cell cycle in neuronal death induced by camptothecin.
Zhang Y; Qu D; Morris EJ; O'Hare MJ; Callaghan SM; Slack RS; Geller HM; Park DS
J Neurosci; 2006 Aug; 26(34):8819-28. PubMed ID: 16928871
[TBL] [Abstract][Full Text] [Related]
19. The Chk1-Cdc25C regulation is involved in sensitizing A253 cells to a novel topoisomerase I inhibitor BNP1350 by bax gene transfer.
Yin M; Hapke G; Guo B; Azrak RG; Frank C; Rustum YM
Oncogene; 2001 Aug; 20(38):5249-57. PubMed ID: 11536038
[TBL] [Abstract][Full Text] [Related]
20. Cyclin B1 is an efficacy-predicting biomarker for Chk1 inhibitors.
Xiao Z; Xue J; Gu WZ; Bui M; Li G; Tao ZF; Lin NH; Sowin TJ; Zhang H
Biomarkers; 2008 Sep; 13(6):579-96. PubMed ID: 18671143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
